Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are ...

The Week 48 results also showed that participants who initiated treatment with Biktarvy or DTG+F/TDF both had similarly high rates of HIV suppression. Participants who initiated treatment with ...

Biktarvy, Gilead's latest triple therapy, was approved by the FDA in February 2018 as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history ...

This update makes Biktarvy the only second-generation integrase strand transfer inhibitor-based single-tablet regimen with in-label clinical trial data and FDA approval in virologically suppressed ...

Biktarvy is currently lining Gilead’s pockets as the company’s top-selling drug. For the first three months of 2022, Biktarvy pulled down sales of $2.15 billion worldwide.

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to ...

Biktarvy sales jumped 18% from 2021's first quarter to $2.15 billion, while Descovy revenues increased 4% to $374 million. On the flip side, Truvada sales took an expected hit, plummeting 72% ...